{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:32:48Z","timestamp":1791495168522,"version":"4.3.4"},"reference-count":91,"publisher":"American Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:p>Diabetic kidney disease (DKD) is now the principal cause of chronic kidney disease leading to end-stage kidney disease worldwide. As a primary contributor to the excess risk of all-cause and cardiovascular death in diabetes, DKD is a major contributor to the progressively expanding global burden of diabetes-associated morbidity and mortality. Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors are a newer class of antihyperglycemic agents that exert glucose-lowering effects via glycosuric actions. Preclinical studies and clinical trials of SGLT2 inhibitors have consistently demonstrated reduction of albuminuria and preservation of kidney function. In particular, SGLT2 inhibitors lower risk of congestive heart failure, a major cardiovascular complication in DKD. This Perspective summarizes proposed mechanisms of action for SGLT2 inhibitors, integrates these data with results of recent cardiovascular outcomes trials, and discusses clinical applications for patients with DKD. The American Diabetes Association\/European Association for the Study of Diabetes Consensus Report published online in October 2018 recommends SGLT inhibitors as preferred add-on therapy for patients with type 2 diabetes and established cardiovascular disease or chronic kidney disease, if kidney function is adequate. Results of the ongoing and just completed clinical trials conducted in patients with established DKD will facilitate further refinement of current guidelines.<\/jats:p>","DOI":"10.2337\/dbi18-0007","type":"journal-article","created":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T01:17:05Z","timestamp":1548119825000},"page":"248-257","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":103,"title":["Sodium\u2013Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease"],"prefix":"10.2337","volume":"68","clinical-trial-number":[{"clinical-trial-number":"nct02065791","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03036150","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01131676","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01032629","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01989754","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01730534","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01986881","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02065791","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03036150","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03594110","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03036150","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02421510","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01986881","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03594110","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5437-5700","authenticated-orcid":false,"given":"Radica Z.","family":"Alicic","sequence":"first","affiliation":[{"name":"Providence Health Care, Washington State University, Spokane, WA"},{"name":"University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-7402","authenticated-orcid":false,"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Providence Health Care, Washington State University, Spokane, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Dieter","sequence":"additional","affiliation":[{"name":"Providence Health Care, Washington State University, Spokane, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Providence Health Care, Washington State University, Spokane, WA"},{"name":"University of Washington School of Medicine, Seattle, WA"},{"name":"Kidney Research Institute, University of Washington, Seattle, WA"},{"name":"Institute of Translational Health Sciences, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"key":"2022031303420996000_B1","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/jama.2014.11494","article-title":"Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012","volume":"312","author":"Geiss","year":"2014","journal-title":"JAMA"},{"key":"2022031303420996000_B2"},{"key":"2022031303420996000_B3"},{"key":"2022031303420996000_B4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"2022031303420996000_B5","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.ajkd.2006.12.005","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease","volume":"49","author":"KDOQI","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2022031303420996000_B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2012.10.001","article-title":"Epidemiology of diabetic kidney disease","volume":"97","author":"Reutens","year":"2013","journal-title":"Med Clin North Am"},{"key":"2022031303420996000_B7","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Rao Kondapally Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031303420996000_B8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2022031303420996000_B9","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1007\/s00125-010-1860-3","article-title":"In the absence of renal disease, 20\u00a0year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study","volume":"53","author":"Orchard","year":"2010","journal-title":"Diabetologia"},{"key":"2022031303420996000_B10","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/ki.2011.368","article-title":"The contribution of chronic kidney disease to the global burden of major noncommunicable diseases","volume":"80","author":"Couser","year":"2011","journal-title":"Kidney Int"},{"key":"2022031303420996000_B11","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","article-title":"Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy","volume":"390","author":"Levin","year":"2017","journal-title":"Lancet"},{"key":"2022031303420996000_B12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"key":"2022031303420996000_B13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.kint.2017.11.020","article-title":"Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy","volume":"93","author":"Storey","year":"2018","journal-title":"Kidney Int"},{"key":"2022031303420996000_B14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dc13-2112","article-title":"The Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study at 30 years: overview","volume":"37","author":"Nathan","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031303420996000_B15","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031303420996000_B16","first-page":"S91","article-title":"Glucose transporters of the glomerulus and the implications for diabetic nephropathy","volume":"60","author":"Heilig","year":"1997","journal-title":"Kidney Int Suppl."},{"key":"2022031303420996000_B17","first-page":"793","article-title":"The role of cellular glucose transporters in pathogenesis of diabetic nephropathy","volume":"56","author":"Witowski","year":"1999","journal-title":"Przegl Lek"},{"key":"2022031303420996000_B18","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1590\/1806-9282.63.07.636","article-title":"Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus","volume":"63","author":"Santos","year":"2017","journal-title":"Rev Assoc Med Bras"},{"key":"2022031303420996000_B19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","article-title":"Active sugar transport in health and disease","volume":"261","author":"Wright","year":"2007","journal-title":"J Intern Med"},{"key":"2022031303420996000_B20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabet Med"},{"key":"2022031303420996000_B21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mam.2012.11.002","article-title":"Glucose transport families SLC5 and SLC50","volume":"34","author":"Wright","year":"2013","journal-title":"Mol Aspects Med"},{"key":"2022031303420996000_B22","doi-asserted-by":"crossref","first-page":"F467","DOI":"10.1152\/ajprenal.00628.2016","article-title":"Characterization of the transport activity of SGLT2\/MAP17, the renal low-affinity Na+-glucose cotransporter","volume":"313","author":"Coady","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031303420996000_B23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J Clin Invest"},{"key":"2022031303420996000_B24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0168-8227(97)01389-2","article-title":"Renal threshold for glucose in non-insulin-dependent diabetic patients","volume":"36","author":"Ruhnau","year":"1997","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031303420996000_B25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/BF00252403","article-title":"Variations in renal threshold for glucose in type 1 (insulin-dependent) diabetes mellitus","volume":"26","author":"Johansen","year":"1984","journal-title":"Diabetologia"},{"key":"2022031303420996000_B26","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/ndt\/gfl175","article-title":"Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes--results of a hyperglycaemic glucose clamp study","volume":"21","author":"Rave","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2022031303420996000_B27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2017.07.033","article-title":"Renal glucose metabolism in normal physiological conditions and in diabetes","volume":"133","author":"Alsahli","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031303420996000_B28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/en.2007-1088","article-title":"Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity","volume":"149","author":"Freitas","year":"2008","journal-title":"Endocrinology"},{"key":"2022031303420996000_B29","doi-asserted-by":"crossref","first-page":"26428","DOI":"10.1038\/srep26428","article-title":"Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db\/db mice","volume":"6","author":"Gallo","year":"2016","journal-title":"Sci Rep"},{"key":"2022031303420996000_B30","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/SLA.0b013e3181d96e1f","article-title":"Rapid upregulation of sodium-glucose transporter SGLT1 in response to intestinal sweet taste stimulation","volume":"251","author":"Stearns","year":"2010","journal-title":"Ann Surg"},{"key":"2022031303420996000_B31","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"2022031303420996000_B32","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/dom.13003","article-title":"Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects","volume":"19","author":"Norton","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2022031303420996000_B33","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031303420996000_B34","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031303420996000_B35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"2022031303420996000_B36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031303420996000_B37","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1007\/s00125-018-4644-9","article-title":"Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME\u00ae randomised trial","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"2022031303420996000_B38","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031303420996000_B39","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"key":"2022031303420996000_B40","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/dom.13217","article-title":"DECLARE-TIMI 58: participants\u2019 baseline characteristics","volume":"20","author":"Raz","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022031303420996000_B41","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000484633","article-title":"The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics","volume":"46","author":"Jardine","year":"2017","journal-title":"Am J Nephrol"},{"key":"2022031303420996000_B42","unstructured":"Janssen Global Services. Phase 3 CREDENCE renal outcomes trial of INVOKANA (canagliflozin) is being stopped early for positive efficacy findings [Internet], 16 July 2018. Available from https:\/\/www.janssen.com\/phase-3-credence-renal-outcomes-trial-invokanar-canagliflozin-being-stopped-early-positive-efficacy. Accessed 15 October 2018"},{"key":"2022031303420996000_B43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031303420996000_B44","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"2022031303420996000_B45","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031303420996000_B46","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2022031303420996000_B47","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022031303420996000_B48","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022031303420996000_B49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pcd.2018.02.001","article-title":"SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis","volume":"12","author":"Seidu","year":"2018","journal-title":"Prim Care Diabetes"},{"key":"2022031303420996000_B50","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1007\/s00125-016-4017-1","article-title":"Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment","volume":"59","author":"Fioretto","year":"2016","journal-title":"Diabetologia"},{"key":"2022031303420996000_B51","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/dom.12936","article-title":"The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients","volume":"19","author":"Petrykiv","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2022031303420996000_B52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.diabet.2014.10.003","article-title":"The impact of hyperfiltration on the diabetic kidney","volume":"41","author":"Premaratne","year":"2015","journal-title":"Diabetes Metab"},{"key":"2022031303420996000_B53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dbi16-0056","article-title":"Back to the future: glomerular hyperfiltration and the diabetic kidney","volume":"66","author":"Tuttle","year":"2017","journal-title":"Diabetes"},{"key":"2022031303420996000_B54","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"2022031303420996000_B55","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MNH.0000000000000084","article-title":"Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy","volume":"24","author":"\u0160krti\u0107","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2022031303420996000_B56","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031303420996000_B57","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","article-title":"Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption","volume":"10","author":"Vallon","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"2022031303420996000_B58","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2022031303420996000_B59","first-page":"191","article-title":"Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation","volume":"48","author":"Ishibashi","year":"2016","journal-title":"Horm Metab Res"},{"key":"2022031303420996000_B60","doi-asserted-by":"crossref","first-page":"E1083","DOI":"10.3390\/ijms18051083","article-title":"SGLT2 inhibitors as a therapeutic option for diabetic nephropathy","volume":"18","author":"Kawanami","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2022031303420996000_B61","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0034-1395609","article-title":"Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis","volume":"47","author":"Ojima","year":"2015","journal-title":"Horm Metab Res"},{"key":"2022031303420996000_B62","doi-asserted-by":"crossref","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","article-title":"The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension","volume":"307","author":"Gembardt","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031303420996000_B63","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"2022031303420996000_B64","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of phase III trials indicate contrasting influences of renal function on blood\u00a0pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int"},{"key":"2022031303420996000_B65","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocr Rev"},{"key":"2022031303420996000_B66","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.pcd.2017.04.004","article-title":"Dapagliflozin therapy for type 2 diabetes in primary care: changes in HbA1c, weight and blood pressure over 2 years follow-up","volume":"11","author":"Wilding","year":"2017","journal-title":"Prim Care Diabetes"},{"key":"2022031303420996000_B67","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031303420996000_B68","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"2022031303420996000_B69","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jdiacomp.2015.07.011","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years","volume":"29","author":"Liu","year":"2015","journal-title":"J Diabetes Complications"},{"key":"2022031303420996000_B70","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00228-014-1730-x","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis","volume":"70","author":"Yang","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"2022031303420996000_B71","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/1573402111666150530204136","article-title":"Mechanisms of salt-sensitive hypertension","volume":"11","author":"Luzardo","year":"2015","journal-title":"Curr Hypertens Rev"},{"key":"2022031303420996000_B72","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s12325-016-0457-8","article-title":"Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus","volume":"34","author":"Tanaka","year":"2017","journal-title":"Adv Ther"},{"key":"2022031303420996000_B73","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022031303420996000_B74","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.atherosclerosis.2012.05.022","article-title":"Reductions in arterial stiffness with weight loss in overweight and obese young adults: potential mechanisms","volume":"223","author":"Cooper","year":"2012","journal-title":"Atherosclerosis"},{"key":"2022031303420996000_B75","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"2022031303420996000_B76","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.2337\/dc13-0506","article-title":"Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio deJaneiro Type 2 Diabetes Cohort Study","volume":"36","author":"Cardoso","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031303420996000_B77","first-page":"F946","article-title":"Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus","volume":"260","author":"Pollock","year":"1991","journal-title":"Am J Physiol"},{"key":"2022031303420996000_B78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00232-001-0036-y","article-title":"Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat","volume":"182","author":"Vestri","year":"2001","journal-title":"J Membr Biol"},{"key":"2022031303420996000_B79","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2022031303420996000_B80","doi-asserted-by":"crossref","first-page":"C1569","DOI":"10.1152\/ajpcell.00017.2012","article-title":"Deciphering the mechanisms of the Na+\/H+ exchanger-3 regulation in organ dysfunction","volume":"302","author":"Girardi","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"key":"2022031303420996000_B81","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2013060588","article-title":"Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+\/H+ exchanger isoform 3 activity in the renal proximal tubule","volume":"25","author":"Pessoa","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022031303420996000_B82","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/cd17-0119","article-title":"Standards of Medical Care in Diabetes\u20142018 abridged for primary care providers","volume":"36","author":"American Diabetes Association","year":"2018","journal-title":"Clin Diabetes"},{"key":"2022031303420996000_B83","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4158\/CS-2017-0153","article-title":"Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary","volume":"24","author":"Garber","year":"2018","journal-title":"Endocr Pract"},{"key":"2022031303420996000_B84","doi-asserted-by":"crossref","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","author":"Davies","year":"2018;41:2669\u20132701","journal-title":"Diabetes Care"},{"key":"2022031303420996000_B85"},{"key":"2022031303420996000_B86"},{"key":"2022031303420996000_B87"},{"key":"2022031303420996000_B88","unstructured":"Sanofi. A phase 3 study to evaluate the safety of sotagliflozin in patients with type 1 diabetes who have inadequate glycemic control with insulin therapy alone (inTandem3). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2017. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02531035. NLM Identifier: NCT02531035. Accessed 15 October 2018"},{"key":"2022031303420996000_B89","unstructured":"Sanofi. Efficacy, safety, and tolerability study of sotagliflozin as adjunct therapy in adult patients with type 1 diabetes mellitus who have inadequate glycemic control with insulin therapy (inTandem2). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2017. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02421510. NLM Identifier: NCT02421510. Accessed 15 October 2018"},{"key":"2022031303420996000_B90","unstructured":"Merck Sharp & Dohme Corp. Cardiovascular outcomes following ertugliflozin treatment in type 2 diabetes mellitus. participants with vascular disease, the VERTIS CV Study (MK-8835-004). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2018. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01986881. NLM Indentifier: NCT01986881. Accessed 15 October 2018"},{"key":"2022031303420996000_B91","unstructured":"Boehringer Ingelheim. EMPA-KIDNEY (The study of heart and kidney protection with empagliflozin). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2018. Available from https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03594110. NLM Identifier: NCT03594110. Accessed 15 October 2018"}],"updated-by":[{"DOI":"10.2337\/db19-er05a","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000}}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/68\/2\/248\/523734\/dbi180007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/68\/2\/248\/523734\/dbi180007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:37:17Z","timestamp":1667407037000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/68\/2\/248\/39854\/Sodium-Glucose-Cotransporter-2-Inhibition-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":91,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,1,14]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dbi18-0007","relation":{"correction":[{"id-type":"doi","id":"10.2337\/db19-er05a","asserted-by":"object"}]},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]}}}